drugset / Trial / NCT03961828

Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus

NCT03961828

Phase 4 Completed 50 enrolled Tanta University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients with transfusion dependent Beta Thalassemia suffer from a high incidence of Hepatitis C infection especially in developed countries as Egypt. In our patients we also found a high correlation between hepatitic C infection and Liver fibrosis. in this study we offer our patients treatment with Direct antiviral drugs and assessed the degree of fibrosis before and after treatment. We tested Hyalornic acid as a predictor of the degree of fibrosis before and after treatment.

Timeline

Start
2017-10-01
Primary completion
2018-12-31
Completion
2019-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ledipasvir Small molecule 90 mg Oral
Subject Sofosbuvir Small molecule 400 mg Oral